STEMRIM |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 463 JPY | +3.12% |
|
+1.31% | -19.90% |
| May. 09 | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
| Mar. 13 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 181M | - | - | - | |||
| 89.87B | ||||||
| 37.57B | ||||||
| 32.75B | ||||||
| 26.47B | ||||||
| 14.25B |
- Stock Market
- Equities
- 4599 Stock
- Charts StemRIM
- Sector Chart
